Novartis Files Suit To Block Barr From Marketing Generic Ritalin LA
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr’s ANDA with Paragraph IV certification was accepted by FDA in September, generics firm says.
You may also be interested in...
Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity
The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.